

# Cytimmune

*An oncology company*

Pioneering the delivery of high dose  
cytokine combination therapeutics

**Presentation by: David Oarr ([doarr@cytimmune.com](mailto:doarr@cytimmune.com))**

# The Problem

Solid tumor cancers are hard to treat to because:



**Toxic  
Therapies**



**Impenetrable  
Tumors**



**Immuno-suppressive  
Cancers**

# A Pan-Solid Tumor Solution


## Cytokine Powered Nanoparticles

### Cytokines (Too Toxic)

- Crack open solid tumors
- Stimulate an immune response
- Work in combinations


### Nanoparticles (Can't penetrate tumors)

- Target tumors
- Deliver high therapeutic doses safely
- Cytokines, Biologics, Small Molecules



Cytokines on Nanoparticle Platform  
Open the tumor → Enable High Dose Combination Therapies

# Market Opportunity




**\$424.6B by 2027**

Global Solid Tumor Therapeutics

# Competition




Platform Patents



Dose & Safety



Targeted Delivery



Combination Therapy

**Philogen**  
innovating targeting


**Alkermes**<sup>®</sup>

**x·iliō**  
THERAPEUTICS

 **Rubius**Therapeutics

**Werewolf**  
THERAPEUTICS 

# Traction



EVERSHEDS  
SUTHERLAND

SCENDEA  
COLLABORATE | INNOVATE | SUCCEED



**NIST**  
National Institute of  
Standards and Technology



**BC** Bioconjugate  
Chemistry

nature

# cytimmune Team



**Saba Makak**  
CEO



**David Oarr**  
President



**Giulio Paciotti**  
Founder / CSO



**Wendy Nelson**  
Business Development



**Shelia Violette**  
Board Member



**Fred Paster**  
Board Member



**20+ yrs Nanomedicine Experience**  
**100+ yrs Industry Experience**



**JOHNS HOPKINS**  
UNIVERSITY




National Institutes  
of Health



**biogen idec**

**ALEXION**



# Financials

EXIT   
INVESTMENTS 

10M

2022

60M

2023

2024

First-Look  
Clinical Data



120M

2025

2026

Phase 1 & 2  
Clinical Data



2027

2022

2023

2024

2025

2026

2027



# Investment

**\$30M**

**INVESTMENTS**

**\$10M**

**ASK**

## Utilization

- Drug manufacturing
- Clinical Activities
- Partnering Activities



# Cytimmune

**CEO: Saba Malak**

[smalak@cytimmune.com](mailto:smalak@cytimmune.com) +1 617.901.6152

**President: David Oarr**

[doarr@cytimmune.com](mailto:doarr@cytimmune.com) +1 202.725.0477

**CSO: Giulio Paciotti**

[gpaciotti@cytimmune.com](mailto:gpaciotti@cytimmune.com) +1 443.889.3691

**Bios, Board Members and SAB Members are available on**

**Cytimmune's website: <http://cytimmune.com>**

**Rockville, MD & Boston, MA**